At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
LCI699 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Multi-center, Dose Ranging Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Resistant Hypertension
In Brief
A Phase 2 clinical trial evaluating LCI699, Eplerenone, and 2 other interventions for Hypertension. Completed, enrolled 155 participants across 38 sites in 2 countries.
Detailed Summary
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesIceland, United States
CollaboratorsGreat Lakes Drug Development, Inc., Integrium
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedJan 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedJan 6, 2009
Enrollment StartDec 22, 2008
Primary CompletionOct 13, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.5 years ago
Interventions
LCI699drug
LCI699 oral capsules
Eplerenonedrug
Eplerenone oral capsules
LCI699-matching Placebodrug
LCI699-matching placebo oral capsules
Eplerenone-matching Placebodrug
Eplerenone-matching placebo oral capsules